Journal: Genes, chromosomes & cancer

Article Title: Complex IGH Rearrangements in Multiple Myeloma: Frequent Detection Discrepancies Among Three Different Probe Sets

doi: 10.1002/gcc.22158

Figure Lengend Snippet: Locations a of FISH Probes and IGH Enhancers on Chromosome 14

Article Snippet: Previously, we showed that U266 has an atypical primary IGH rearrangement generated by insertion of Eα1 enhancer sequences near Cyclin D1 during IGH switch recombination ( Gabrea, et al. 1999 ); this insertion was detected with the in-house CH and Cytocell IGH C probes but not with the Vysis LSI 3′ flanking probe. table ft1 table-wrap mode="anchored" t5 caption a7 Cell line b Normal fusion signal c Primary translocations Secondary or complex IgH rearrangements #CH,VH signals d Rearrangements #CH,VH signals d Rearrangements Rearrangement type e DP6-DJ 2F 0 0 1CH (0CH) ins CH at 8q24 on der(8)( CH +,VH−,CMYC+,wcp14−) I U266 2F 0 0 1CH (0CH) ins CH at 11q13 on der(11)t(4;11)(?

Techniques:

Journal:

Article Title: Immature dendritic cells possess a sugar-sensitive receptor for human mannan-binding lectin

doi: 10.1046/j.1365-2567.2003.01675.x

Figure Lengend Snippet: MBL and MBL receptors detected by flow cytometry. Cells were labelled with biotinylated anti-MBL antibodies or biotinylated MBL followed by streptavidin–FITC as described in the Materials and Methods. (a) The profile for monocytes labelled with anti-MBL is shown in grey with the outline of the isotype control superimposed as a thick black line. (b) The profile for immature DC labelled with biotinylated MBL in the presence of EDTA is shown in grey with the negative control (unlabelled MBL) outline superimposed as a thick black line. (c) The profile for immature DC labelled with biotinylated MBL in the presence of calcium is shown in grey with the negative control (unlabelled MBL) outline superimposed as a thick black line.

Article Snippet: Cells were labelled with biotinylated anti-MBL antibodies or biotinylated MBL followed by streptavidin–FITC as described in the Materials and Methods. (a) The profile for monocytes labelled with anti-MBL is shown in grey with the outline of the isotype control superimposed as a thick black line. (b) The profile for immature DC labelled with biotinylated MBL in the presence of EDTA is shown in grey with the negative control (unlabelled MBL) outline superimposed as a thick black line. (c) The profile for immature DC labelled with biotinylated MBL in the presence of calcium is shown in grey with the negative control (unlabelled MBL) outline superimposed as a thick black line. table ft1 table-wrap mode="anchored" t5 caption a7 Stage n MBL-positive cells (%) Monocytes (day 0) 21 18·1 + 2·4 Immature DC (day 3) 21 9·8 + 1·2 P < 0·004 Immature DC (day 6) 19 12·4 + 1·8 P < 0·05 Mature DC (day 6) 16 10·1 + 1·3 P < 0·01 Open in a separate window Results are expressed as means + SE.

Techniques: Flow Cytometry, Control, Negative Control

Journal:

Article Title: Immature dendritic cells possess a sugar-sensitive receptor for human mannan-binding lectin

doi: 10.1046/j.1365-2567.2003.01675.x

Figure Lengend Snippet: Inhibition of MBL–MBL receptor interaction by specific monosaccharides. Biotinylated MBL was incubated with immature DC (day 3) and a tripling dilution series of each monosaccharide. (The positive control was obtained in the absence of added sugar). Most results are given by means ± SE of four determinations (but only one determination at 1·2 mm). d-mannose, N-acetyl-D-glucosamine, d-galactose and N-acetyl-D-galactosamine were tested in the presence of 5 mm Ca2+. The broken line represents the corresponding mean value obtained without calcium or sugars in the presence of EDTA.

Article Snippet: Cells were labelled with biotinylated anti-MBL antibodies or biotinylated MBL followed by streptavidin–FITC as described in the Materials and Methods. (a) The profile for monocytes labelled with anti-MBL is shown in grey with the outline of the isotype control superimposed as a thick black line. (b) The profile for immature DC labelled with biotinylated MBL in the presence of EDTA is shown in grey with the negative control (unlabelled MBL) outline superimposed as a thick black line. (c) The profile for immature DC labelled with biotinylated MBL in the presence of calcium is shown in grey with the negative control (unlabelled MBL) outline superimposed as a thick black line. table ft1 table-wrap mode="anchored" t5 caption a7 Stage n MBL-positive cells (%) Monocytes (day 0) 21 18·1 + 2·4 Immature DC (day 3) 21 9·8 + 1·2 P < 0·004 Immature DC (day 6) 19 12·4 + 1·8 P < 0·05 Mature DC (day 6) 16 10·1 + 1·3 P < 0·01 Open in a separate window Results are expressed as means + SE.

Techniques: Inhibition, Incubation, Positive Control

Journal: Oral oncology

Article Title: Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer

doi: 10.1016/j.oraloncology.2019.03.013

Figure Lengend Snippet: Patient and treatment characteristics

Article Snippet: Type E failures occur when the failure is not contained within a therapeutic 95% isodose line. (B) Overview of patterns of failure with regard to treatment volumes. (C) Example case of a patient with a right cT2N1 tonsil squamous cell carcinoma contoured per standard of care and (D) recent consensus guidelines ( 9 , 13 ). (E).Graph of 10 cases contoured per University of Wisconsin's standard of care and recent consensus guidelines as above. table ft1 table-wrap mode="anchored" t5 Table 1: caption a7 Number Percent Age Median 57.5 ≤ 55 57 42.5 > 55 77 57.5 Sex Female 20 16.8 Male 114 83.2 Tumor site Tonsil 62 46.3 Base of tongue 69 51.5 Soft palate 3 2.2 Tobacco use Never 36 26.9 Current smoker 31 23.1 Former smoker 67 50.0 Pack Years Median 10.0 ≤ 10 pack years 66 51.5 > 10 pack years 62 48.4 Unknown pack years 6 4.5 Alcohol use None 13 9.7 0–6 drinks per week 45 33.6 7–20 drinks per week 33 24.6 > 21 drinks per week 21 15.7 Previous heavy drinker 19 14.2 Unknown alcohol history 3 2.2 T stage Tis 2 1.5 T1 24 17.9 T2 56 41.8 T3 21 15.7 T4 31 23.1 N stage N0 9 6.7 N1 80 59.7 N2 38 28.4 N3 7 5.2 Stage I 65 48.5 II 33 24.6 III 36 26.9 Chemotherapy Concurrent cisplatin 85 63.4 Concurrent cetuximab 24 17.9 Neoadjuvant + concurrent 5 3.7 None 20 14.9 Radiotherapy technique Linac-based IMRT 31 23% TomoTherapy-based IMRT 103 77% Open in a separate window Patient and treatment characteristics table ft1 table-wrap mode="anchored" t5 Table 2 – caption a7 Locoregional Recurrence Overall Survival HR p-value 95% CI HR p-value 95% CI Heavy alcohol use vs. moderate or less 1.23 0.71 (0.43–3.53) 1.50 0.26 (0.75–3.01) Smoking ≥ 20 vs < 20 pack years 1.46 0.45 (0.55–3.88) 1.32 0.43 (0.67–2.61) Age ≥ 70 versus < 70 years 5.87 < 0.01 (2.03–16.98) 5.15 < 0.001 (2.16–12.27) Tonsil vs. BOT 1.11 0.83 (0.44–2.82) 1.80 0.09 (0.92–3.54) T4 vs. T1–3 1.66 0.03 (1.04–2.64) 1.45 0.34 (0.67–3.15) N3 vs. N1–2 1.80 0.09 (0.91–3.55) 2.79 0.06 (0.96–8.11) Chemotherapy vs. no chemotherapy 0.50 0.23 (0.16–1.54) 0.80 0.63 (0.32–2.00) Break in radiation vs. no break 1.84 0.55 (0.24–13.98) 2.66 0.19 (0.62–11.30) Multivariate analysis Age > 70 versus ≤ 70 years 5.42 < 0.01 (1.87–15.68) T4 vs. T1–3 4.09 < 0.05 (1.01–2.65) Open in a separate window Univariate and multivariate analysis of locoregional recurrence and overall survival.

Techniques: